论文部分内容阅读
目的检测上皮性卵巢癌中基质金属蛋白酶-2(matrix metalloproteinase-2,MMP-2)及金属蛋白酶组织抑制剂-2(tissue inhibitor of metalloproteinase-2,TIMP-2)的表达水平,并分析其临床意义。方法采用免疫组化染色法检测MMP-2、TIMP-2在上皮性卵巢癌、上皮性良性卵巢肿瘤及正常卵巢组织3组对象卵巢组织中的阳性表达率,分析上皮性卵巢癌患者不同临床病理特征下MMP-2及TIMP-2的阳性表达水平。结果上皮性卵巢癌组卵巢组织MMP-2及TIMP-2的阳性表达率明显高于良性上皮性卵巢肿瘤组和正常卵巢组织组(P<0.05)。MMP-2及TIMP-2在上皮性卵巢癌Ⅲ期+Ⅳ期患者中的阳性表达率明显高于Ⅰ期+Ⅱ期患者(P<0.05);在低分化(G3)患者中的阳性表达率明显高于高、中分化(G1+G2)患者(P<0.05);在有淋巴结转移患者中的阳性表达率明显高于无淋巴结转移患者(P<0.05)。结论 MMP-2和TIMP-2的检测是否可作为早期诊断上皮性卵巢癌的生物指标,尚需进一步研究,但MMP-2及TIMP-2的表达水平与上皮性卵巢癌的临床分期、分化程度、淋巴结转移有关,可作为判断上皮性卵巢癌预后的辅助指标。
Objective To detect the expression of matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinase-2 (TIMP-2) in epithelial ovarian cancer significance. Methods The positive rates of MMP-2 and TIMP-2 in ovarian tissues of 3 groups of epithelial ovarian cancer, benign epithelial ovarian tumor and normal ovarian tissue were detected by immunohistochemical staining. The clinical and pathological features of epithelial ovarian cancer Characteristics of MMP-2 and TIMP-2 positive expression levels. Results The positive expression rate of MMP-2 and TIMP-2 in ovarian epithelial ovarian cancer group was significantly higher than that in benign epithelial ovarian tumor group and normal ovarian tissue group (P <0.05). The positive rates of MMP-2 and TIMP-2 in patients with stage Ⅲ and Ⅳ epithelial ovarian cancer were significantly higher than those in patients with stage Ⅰ and Ⅱ (P <0.05). The positive rates of MMP-2 and TIMP-2 in patients with poorly differentiated (P <0.05). The positive expression rate in patients with lymph node metastasis was significantly higher than that in patients without lymph node metastasis (P <0.05). Conclusion Whether the detection of MMP-2 and TIMP-2 can be used as early biomarkers for the diagnosis of epithelial ovarian cancer requires further study. However, the expression levels of MMP-2 and TIMP-2 are correlated with the clinical stage and differentiation degree of epithelial ovarian cancer , Lymph node metastasis, can be used as a prognostic indicator of epithelial ovarian cancer.